Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial

Trial Profile

Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2014

At a glance

  • Drugs Solifenacin (Primary) ; Tamsulosin (Primary)
  • Indications Lower urinary tract symptoms
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 16 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top